Landis P - Search Results

1

Expectant management of prostate cancer with curative intent: an update of the Johns Hopkins experience.

Carter HB, Kettermann A, Warlick C, Metter EJ, Landis P, Walsh PC, Epstein JI. Carter HB, et al. Among authors: landis p. J Urol. 2007 Dec;178(6):2359-64; discussion 2364-5. doi: 10.1016/j.juro.2007.08.039. Epub 2007 Oct 22. J Urol. 2007. PMID: 17936806 Free PMC article.

2

Change in prostate cancer grade over time in men followed expectantly for stage T1c disease.

Sheridan TB, Carter HB, Wang W, Landis PB, Epstein JI. Sheridan TB, et al. J Urol. 2008 Mar;179(3):901-4; discussion 904-5. doi: 10.1016/j.juro.2007.10.062. Epub 2008 Jan 22. J Urol. 2008. PMID: 18207195 Free PMC article.

3

Expectant management of nonpalpable prostate cancer with curative intent: preliminary results.

Carter HB, Walsh PC, Landis P, Epstein JI. Carter HB, et al. Among authors: landis p. J Urol. 2002 Mar;167(3):1231-4. J Urol. 2002. PMID: 11832703

4

Prostate specific antigen predicts the long-term risk of prostate enlargement: results from the Baltimore Longitudinal Study of Aging.

Wright EJ, Fang J, Metter EJ, Partin AW, Landis P, Chan D, Carter H. Wright EJ, et al. Among authors: landis p. J Urol. 2002 Jun;167(6):2484-7; discussion 2487-8. doi: 10.1016/s0022-5347(05)65010-0. J Urol. 2002. PMID: 11992063

5

PSA velocity for assessing prostate cancer risk in men with PSA levels between 2.0 and 4.0 ng/ml.

Fang J, Metter EJ, Landis P, Carter HB. Fang J, et al. Among authors: landis p. Urology. 2002 Jun;59(6):889-93; discussion 893-4. doi: 10.1016/s0090-4295(02)01646-1. Urology. 2002. PMID: 12031375

6

Can prostate specific antigen derivatives and pathological parameters predict significant change in expectant management criteria for prostate cancer?

Khan MA, Carter HB, Epstein JI, Miller MC, Landis P, Walsh PW, Partin AW, Veltri RW. Khan MA, et al. Among authors: landis p. J Urol. 2003 Dec;170(6 Pt 1):2274-8. doi: 10.1097/01.ju.0000097124.21878.6b. J Urol. 2003. PMID: 14634395

7

Can a baseline prostate specific antigen level identify men who will have lower urinary tract symptoms later in life?

Carter HB, Landis P, Wright EJ, Parsons JK, Metter EJ. Carter HB, et al. Among authors: landis p. J Urol. 2005 Jun;173(6):2040-3. doi: 10.1097/01.ju.0000158372.45211.47. J Urol. 2005. PMID: 15879821

8

Serum testosterone and the risk of prostate cancer: potential implications for testosterone therapy.

Parsons JK, Carter HB, Platz EA, Wright EJ, Landis P, Metter EJ. Parsons JK, et al. Among authors: landis p. Cancer Epidemiol Biomarkers Prev. 2005 Sep;14(9):2257-60. doi: 10.1158/1055-9965.EPI-04-0715. Cancer Epidemiol Biomarkers Prev. 2005. PMID: 16172240

9

Delayed versus immediate surgical intervention and prostate cancer outcome.

Warlick C, Trock BJ, Landis P, Epstein JI, Carter HB. Warlick C, et al. Among authors: landis p. J Natl Cancer Inst. 2006 Mar 1;98(5):355-7. doi: 10.1093/jnci/djj072. J Natl Cancer Inst. 2006. PMID: 16507832 Free PMC article.

10

Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability.

Carter HB, Ferrucci L, Kettermann A, Landis P, Wright EJ, Epstein JI, Trock BJ, Metter EJ. Carter HB, et al. Among authors: landis p. J Natl Cancer Inst. 2006 Nov 1;98(21):1521-7. doi: 10.1093/jnci/djj410. J Natl Cancer Inst. 2006. PMID: 17077354 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

104 results

Search Page

Filters